FKBP ligands—where we are and where to go?
JM Kolos, AM Voll, M Bauder, F Hausch - Frontiers in pharmacology, 2018 - frontiersin.org
In recent years, many members of the FK506-binding protein (FKBP) family were
increasingly linked to various diseases. The binding domain of FKBPs differs only in a few …
increasingly linked to various diseases. The binding domain of FKBPs differs only in a few …
FKBP51 and FKBP52 in signaling and disease
CL Storer, CA Dickey, MD Galigniana, T Rein… - Trends in Endocrinology …, 2011 - cell.com
FKBP51 and FKBP52 are diverse regulators of steroid hormone receptor signaling,
including receptor maturation, hormone binding and nuclear translocation. Although …
including receptor maturation, hormone binding and nuclear translocation. Although …
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
Background The androgen receptor (AR) is a pivotal drug target for the treatment of prostate
cancer, including its lethal castration-resistant (CRPC) form. All current non-steroidal AR …
cancer, including its lethal castration-resistant (CRPC) form. All current non-steroidal AR …
Cooperative dynamics of AR and ER activity in breast cancer
NC D'Amato, MA Gordon, B Babbs, NS Spoelstra… - Molecular cancer …, 2016 - AACR
Androgen receptor (AR) is expressed in 90% of estrogen receptor alpha–positive (ER+)
breast tumors, but its role in tumor growth and progression remains controversial. Use of two …
breast tumors, but its role in tumor growth and progression remains controversial. Use of two …
Biological actions of the Hsp90-binding immunophilins FKBP51 and FKBP52
NR Zgajnar, SA De Leo, CM Lotufo, AG Erlejman… - Biomolecules, 2019 - mdpi.com
Immunophilins are a family of proteins whose signature domain is the peptidylprolyl-
isomerase domain. High molecular weight immunophilins are characterized by the …
isomerase domain. High molecular weight immunophilins are characterized by the …
Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.
NA Lack, P Axerio-Cilies, P Tavassoli… - Journal of medicinal …, 2011 - ACS Publications
The androgen receptor (AR) is the best studied drug target for the treatment of prostate
cancer. While there are a number of drugs that target the AR, they all work through the same …
cancer. While there are a number of drugs that target the AR, they all work through the same …
Gedunin Inactivates the Co-chaperone p23 Protein Causing Cancer Cell Death by Apoptosis*♦
Pharmacological inhibition of Hsp90 is an exciting option for cancer therapy. The clinical
efficacy of Hsp90 inhibitors is, however, less than expected. Binding of the co-chaperone …
efficacy of Hsp90 inhibitors is, however, less than expected. Binding of the co-chaperone …
The similarities and differences between the effects of testosterone and DHEA on the innate and adaptive immune response
FO Buendía-González, M Legorreta-Herrera - Biomolecules, 2022 - mdpi.com
Androgens are steroids that modulate various processes in the body, ranging from
reproduction, metabolism, and even immune response. The main androgens are …
reproduction, metabolism, and even immune response. The main androgens are …
Inhibitors and chemical probes for molecular chaperone networks
JE Gestwicki, H Shao - Journal of Biological Chemistry, 2019 - ASBMB
The molecular chaperones are central mediators of protein homeostasis. In that role, they
engage in widespread protein–protein interactions (PPIs) with each other and with their" …
engage in widespread protein–protein interactions (PPIs) with each other and with their" …
Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease
Introduction: Alzheimer's disease, characterized by the accumulation of
hyperphosphorylated tau and β amyloid (Aβ), currently lacks effective treatment. Chaperone …
hyperphosphorylated tau and β amyloid (Aβ), currently lacks effective treatment. Chaperone …